Preparation & Measurement Guide

KLOW Blend 80mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a KLOW Blend 80mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size 10mg BPC-157 + 10mg TB-500 + 10mg KPV + 50mg GHK-CU
Preparation 2mL bacteriostatic water
Concentration 40mg/mL after preparation
Documented Convention 2-6mg total once daily

1. Preparation and Measurement

KLOW Blend 80mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 40mg/mL. On a U-100 syringe, each unit contains 400mcg.

80mg / 2mL = 40mg/mL
1 U-100 unit = 0.01mL = 400mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 2mg total once daily 0.05mL / 5 units
Weeks 3-4 4mg total once daily 0.1mL / 10 units
Weeks 5-8 6mg total once daily 0.15mL / 15 units

Vial estimate: One 80mg vial contains approximately 40 administrations at the first listed amount or 13 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • At 5 units: 250mcg BPC-157, 250mcg TB-500, 250mcg KPV, and 1.25mg GHK-CU.
  • At 10 units: 500mcg BPC-157, 500mcg TB-500, 500mcg KPV, and 2.5mg GHK-CU.
  • At 15 units: 750mcg BPC-157, 750mcg TB-500, 750mcg KPV, and 3.75mg GHK-CU.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • KLOW Blend 80mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

KLOW combines BPC-157, TB-500, KPV, and GHK-CU in a fixed ratio. The exact four-component blend has not been evaluated in controlled human trials.

Research on individual components cannot establish the combined material's safety, efficacy, interactions, or optimal schedule. The table records a circulated total-mass convention only.

Primary Research and Regulatory References

  1. BPC-157 rat Achilles tendon study
  2. Thymosin beta-4 wound-healing research
  3. KPV intestinal inflammation study
  4. Copper peptide tissue-remodelling review

Research Materials

Review KLOW Blend 80mg Product Information

View KLOW Blend 80mg Browse Peptide Blends

← Back to Dosage Protocols

Research-use disclaimer: KLOW Blend 80mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.